BACK

Tim Opler, Ph.D.

Tim Opler, Ph.D.

Partner and Co-Founder

New York Office  |  tim.opler@torreya.com   |   212.257.5802

Tim Opler, a Partner and Co-Founder of Torreya, manages client relationships and oversees the firm’s administrative activities.

Tim has 24 years experience leading strategic and financing transactions across multiple sectors. For nearly 20 years, he has focused exclusively on life sciences advisory; he has completed more than 150 financing, licensing, and M&A transactions across the industry with a total value of over $100 billion. Highlights include running the largest share buyback in history for Pfizer, leading a $3.9 billion convertible bond exchange for Amgen, working on Chiron’s $5.1 billion sale to Novartis, and managing Genentech’s inaugural $2 billion bond issue.

Before co-founding Torreya, Tim was Vice President of Strategy at FibroGen, where he helped raise $117 million for the company and negotiated licensing deals. Previously, Tim was a Managing Director in Healthcare Investment Banking at Credit Suisse First Boston and held senior roles at W.R. Hambrecht, Deutsche Bank, and Merrill Lynch.

Other notable transactions on which Tim advised prior to starting Torreya include advising Pfizer on the sales of Heumann, Dorom, and NM Pharma; managing $1.1 billion in swaps and bond issues for Eli Lilly; managing $150 million in derivatives for Guidant; managing $850 million in bond issuance and swaps for Bristol-Myers Squibb; acting as a lead on Glaxo’s $1 billion bond issue; and leading a $600 million Eurobond issue for Pfizer. He has also led transactions and served as a strategic advisor for BHP, BMW, BP, Coca-Cola Enterprises, Daimler, Dell, Diageo, Dow, Ford, GE, GM, the State of Israel, Microsoft, Philip Morris, the State of Poland, and Royal Dutch Shell, among others.

Prior to his career in investment banking, Tim was a professor in the finance department at Ohio State University. He earned a B.S. in economics and philosophy from Florida State University, and a Ph.D. in economics from UCLA.

Tim is a registered representative with Financial West Group.

Selected Transactions

Sandoz
Sale of
generics portfolio to
FosunPharma
$18 million
August 2017
Sawai
Acquisition of
generics business of
Upsher-Smith
$1.05 billion
June 2017
Selexis
Company sale to
JSR Life Sciences
Undisclosed
June 2017
Assembly Biosciences
Microbiome partnership with
Allergan
$2.6 billion
($50 million upfront)
January 2017
Chelsea Therapeutics
Sale to
Lundbeck
$658 million
June 2014
CombiMatrix
Merger with
Invitae Corporation
$34.9 million
November 2017
XOMA
License of
Gevokizumab and
certain associated IP to
Novartis
$31 million upfront
August 2017
Cipher
Sale of US dermatology business to
EPI
$13.6 million
May 2017
Wafergen Biosystems
Company sale to
Takara
$35.9 million
March 2017
XOMA
Sale of royalties to
Healthcare Royalty Partners
$22 million
December 2016
Apollo Endosurgery
Merger with
Lpath
$251 million
December 2016
Conatus Pharmaceuticals
Collaboration agreement for Emricasan with
Novartis
$50 million upfront
December 2016
Female Health
Has merged with
Aspen Park Pharma
to form
Veru
Undisclosed
November 2016
SciDose
Partial sale of royalty
and milestones
Undisclosed
$40 million
September 2016
IntelgenX
Partial royalty and milestone sale to
SWK Holdings
$6 million
August 2016
Cardiome
Licensing of
Dalbavancin from
Allergan
$13 million upfront
May 2016
Cambrooke Therapeutics
Preferred equity investment
undisclosed
$7 million
January 2016
XOMA
Sale of
biologics manufacturing
facilities to
Agenus
$5 million in cash +
$1 million in stock
November 2015
XOMA
License of global rights
for Anti-TGF-beta
antibody program to
Novartis
Up to $517 million
October 2015
Phenex
Sale of FXR program to
Gilead
Up to $470 million
January 2015
Flamel Technologies
Sale of Pessac plant to
Recipharm AB
Up to €22 million
November 2014
PDI
Acquisition of
Redpath Integrated Pathology
Up to $35 million
October 2014
DBV Technologies
Global offering advisory
Undisclosed
$133 million
October 2014
ABT Molecular Imaging
Synthetic royalty
financing from
SWK Holdings
$10 million
October 2014
Innovative Therapies
Sale to
Cardinal Health
$65 million
September 2014
Ventrus Biosciences
Merger with
Assembly Pharmaceuticals
$24 million
July 2014
Fibrotech
Sale to
Shire
$75 million upfront + milestones
May 2014
Compugen
Financial advisor on
follow-on offering
Undisclosed
$72.5 million
February 2014
Pinnacle Biologics
Sale to
Concordia Healthcare
Undisclosed
December 2013
Correvio
Sale to
Cardiome
19.9% of shares +
$12 million
November 2013
DBV Technologies
Financial advisor in
private placement
Undisclosed
€29.9 million
November 2013
Compugen
Advisor on oncology partnership with
Bayer
$550 million with
$10 million upfront
August 2013
Inviragen
Sale of
vaccine company to
Takeda
$250 million with
$35 million upfront
May 2013
Shionogi
Divestiture of three pediatric drugs to
Concordia Pharmaceuticals
$28.7 million
May 2013
Selexis
Sale of basket of
royalties to
Ligand
$6 million upfront
April 2013
Clinigen
Acquisition of EU rights
to Vibativ® from
Theravance
$5 million + royalties
March 2013
Molecular Insight
Sale for up to
$106 million to
Progenics
$12 million +
milestones
January 2013
SpePharm
Collaboration with
Norgine
Undisclosed
December 2012
GTx
Sale of Fareston® to
Prostrakan/Kyowa Hakko Kirin
$21.7 million
October 2012
Xanodyne
Sale of
Amicar® rights to
Versapharm
Undisclosed
August 2012
Shionogi
Divestiture of
Cuvposa® to
Merz
Undisclosed
August 2012
Xanodyne
Sale of
Roxicodone® to
Covidien
Undisclosed
August 2012
Xanodyne
Sale of Zipsor® to
Depomed
Undisclosed
June 2012
Hedge Fund
Structured debt transaction linked to
three pharma royalties
Pharmakon
$65 million
December 2011
Amorcyte
Sale to
Neostem
$10 million +
milestones
October 2011
Ventrus Biosciences
Financial advisor in
follow-on financing
for GI company
Undisclosed
Undisclosed
July 2011
Aegera Therapeutics
Sale of Canadian biotechnology
company to
Pharmascience
Undisclosed
May 2011
Xanodyne
Co-promotion for
Zipsor®
Medimetriks
Undisclosed
May 2011
Hedge Fund
Sale of
royalties for Cubicin®
and Lexiscan® to
Royalty Pharma
$487 million
April 2011
Lpath
Advisor in
iSonep license to
Pfizer
$500 million with
$14 million upfront
December 2010
Quinnova
Sale of dermatology specialty pharma
business to
Amneal
Undisclosed
December 2010
Three Rivers Pharma
Sale to
Kadmon
$100+ million
October 2010
GTCR
Advisor in the acquisition of six products from
UCB
Undisclosed
July 2010
Columbia Labs
Sale of
Crinone® & Prochieve® product lines and
shares to
Watson
$92.5 million with
$47 million upfront
July 2010
DNP
Acquisition of
Thorne Research
$40 million +
milestones
June 2010
Shareholder Group
Advisor to Genentech
major shareholder
in sale to
Roche
$46 billion
March 2009
AGI Dermatics
Sale to
Estée Lauder
Undisclosed
September 2008
ProEthic Pharma
Sale to
Kowa Pharmaceuticals
Undisclosed
April 2008